NCT06097767View on ClinicalTrials.gov

the Incidence of Necrotizing Enterocolitis in Preterm With Respiratory Distress Syndrome Undergoing Caffeine Therapy

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 19, 2023

Primary Completion Date

April 1, 2024

Study Completion Date

July 30, 2024

Conditions
Pharmacological Action of Drug
Interventions
DRUG

Caffeine citrate

It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.

DRUG

Amikacin

it includes preterm infants with respiratory distress syndrome who received amikacin in regular intervention therapy in control group

Trial Locations (1)

Unknown

NICU at Alzahraa University Hospital, Cairo

All Listed Sponsors
lead

Al-Azhar University

OTHER